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1. Introduction 
Although the global importance of RSV as a respiratory pathogen has been recognized for 
over 40 years, suitable prophylactic and therapeutic interventions have not been truly 
available. Vaccine development, unfortunately, has been fraught with spectacular failure 
and with difficult obstacles, and there are only limited therapeutic options for treatment of 
this disease. Currently, the only approved prophylactic options available involve the use of 
Palivizumab and its derivative Motivizumab (currently under trial) which are both 
monoclonal antibodies directed against RSV surface fusion protein. Ribavirin, a broad-
spectrum anti-viral agent, is the only therapeutic option employed as adjunctive therapy for 
the sickest patients; however, its efficacy has been called into question by multiple studies, 
and most institutions no longer use it. Moreover, the use of both agents has been shown to 
be costly and difficult to handle. Therefore, the search for novel anti-viral inhibitors of RSV 
has become more intensive. It could be recalled that potent anti-viral agents have previously 
been harnessed from medicinal plants. Since medicinal plants have consistently served as 
suitable lead sources for potent anti-viral agents, efforts have also been made by several 
investigators in developing anti-RSV compounds from phytomedicine. In this present 
research paper, we present a review of the past to present activities involving the discovery 
and development of novel and effective anti-RSV compounds from phytomedicine. First, we 
begin by briefly describing the problem of the global disease burden of RSV as well as 
efforts and approaches so far adopted to contain the viral menace. In the next section we 
introduce the subject of phytomedicine and anti-RSV therapeutic products originating from 
various reported medicinal plants. Straightforward and discreet description is made of 
investigations carried out by our workgroup in our attempt to develop anti-RSV compounds 
from medicinal plants especially Ramalina farinaceae and Aglaia ignea. Here also in this 
section, we present and discuss published results from other investigators regarding 
compounds from other medicinal plant sources. The importance of the process and 
techniques leading to their identification and isolation is highlighted. Attention is drawn to 
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some common markers that characterize their discovery. We devote tables to give 
comprehensive listings and profile of these agents and also discuss other relevant results. 
Attempt is made to shed adequate light on the therapeutic efficacy to safety profile of 
promising compounds since the overall relevance of the compounds and their derivatives 
should depend largely on their efficacy-safety characteristics. Additionally, space is devoted 
to discuss the proffered or validated mechanistic bases of the observed the anti-viral and 
disease inhibitory activities of the phytoconstituents and compounds. The importance of 
structural modifications is equally reflected where applicable to grant a quick and early 
preview on the more likely positive alteration direction that could possibly select for 
enhancement of efficacy and cellular compatibility. Lastly, we discuss in the next section the 
promises and the crucial position occupied by anti-RSV compounds and phyto-constituents 
harnessed form phytomedicines in the treatment and control of RSV infection and disease. 
In conclusion, we comment on the future of RSV infection and disease control; the role that 
should expectedly be occupied by chemotherapy, especially phytomedicines-derived. In 
answering the questions of discovering and developing the tomorrow’s effective anti-RSV 
compounds, we make some concluding remarks on some key performance indicators that 
should characterize the phytocompounds of desirable anti-RSV activity. 
1.1 Respiratory syncytial virus 
Respiratory syncytial virus (RSV) which belongs to the Pneumovirus genus of the 
Paramyxoviridae family is the most important cause of viral lower respiratory tract illness 
(LRI) in infants and children worldwide (Collins et al. 1996; Hall, 1994). Amongst children in 
the US, up to 125,000 RSV-associated hospitalizations and 500 RSV-associated deaths 
respectively could occur each year (Langley and Anderson, 2011). RSV was, on average, 
responsible for 17% of acute respiratory infections in children admitted to hospital in the 
developing countries (Martins et al. 1998), and studies from Africa have equally reported the 
influence of malnutrition on the prevalence of RSV (Adegbola et al. 1994; Nwankwo et al. 1994). 
In Nigeria it is reported that RSV infections occur all year round with a peak during the rainy 
season (Nwankwo et al. 1994). Infants who are premature (Berkovich, 1964; Cunningham et al. 
1991) or have chronic lung disease (Groothuis et al. 1988) or congenital heart disease 
(MacDonald et al. 1982) are at particular risk for severe RSV disease. Although traditionally 
regarded as a pediatric pathogen, RSV can also cause life-threatening pulmonary disease in 
bone marrow transplant recipients (Fouillard et al. 1992) and the elderly (Dowell et al. 1996; 
Falsey et al. 1992, 1995, 2005; Falsey and Walsh, 1998). Although the global prevalence of RSV 
infection especially among infants and young children is on the increase, vaccine 
development, unfortunately, has been fraught with spectacular failure and with difficult 
obstacles, and there are only limited therapeutic options for treatment of this disease (Collins et 
al., 1996; Wright et al., 2000; Kohlmann et al., 2009; Tregoning and Schwarze et al., 2010). 
Therefore, the search for novel anti-viral inhibitors of RSV has become more intensive. 
1.2 Phytomedicine and anti-viral agents  
Natural products from plants traditionally have provided the pharmaceutical industry with 
one of its most important sources of lead compounds and up to 40% of modern drugs are 
derived from natural sources, using either the natural substance or a synthesized version. 
Currently, over a 100 new products are in clinical development, particularly as anti-cancer 
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agents and anti-infectives (Gautam et al., 2007; Harvey, 2008; Jassim and Naji, 2003). This has 
influenced many of pharmaceutical companies to produce new antimicrobial formulations 
extracted from plants or herbs. The bioactive molecules occur in plants as secondary 
metabolites and as defense mechanisms against predation, herbivores, fungal attack, 
microbial invasion and viral infection. During the past decade, potent agents have become 
available against viral infections. Therefore, extracts of plants and phytochemicals are 
getting more important as potential sources for viral inhibitors during the recent decade. 
Extensive studies have shown that medicinal plants of several parts of the world contain 
compounds active against viruses that cause human diseases (Kott et al., 1999; Semple et al., 
1998; Sindambiwe et al., 1999). Correspondingly, several potent agents against the 
respiratory virus- RSV have been reported. The aim of this review is to give a 
comprehensive outlook on the available and emerging promising phyto-constituents 
effective against RSV and an overview of the reported associated researches done so far. 
This review encompassed introduction, methodology, outcomes, and overall promises of 
the discovered putative anti-RSV agents. Furthermore, useful guiding components for 
future discovery and analysis of promising anti-RSV candidates are equally highlighted.  
2. Plant species possessing anti-respiratory syncytial virus anti-viral 
activities 
2.1 Aglaia species 
Aglaia represents the largest genus within the family Meliaceae and contains more than 
100 species (Bohnenstengel et al. 1999; Pannell 1992). It is a woody small or medium- sized 
tree found mostly in Southeast Asia. Extracts or pure compounds from the various species 
have been shown to display diverse biological activities ranging from anti-proliferation, 
anti-inflammatory, fungicidal, bactericidal, anthelminthic and anti-viral activity 
(Bohnenstengel et al. 1999; Lipipun et al. 2003; Perry 1980; Poehland et al. 1987). Although 
Aglaia species are traditionally used in Southeast Asia and Indo-China for the treatment of 
various diseases, including ailments related to lower respiratory tract infection and 
inflammation (Lipipun et al. 2003; Perry 1980), anti-viral screening with Aglaia species has 
essentially been limited to Herpes Simplex Virus types 1 and 2 (Lipipun et al. 2003; 
Poehland et al. 1987). Given that RSV infection has a strong bearing with inflammation of 
the lower respiratory tract, we decided to explore various compounds from these species 
for possible anti-RSV activities in vitro. 
Our investigation (Esimone et al., 2008) involving the isolation and screening of eighteen (18) 
compounds from various species of Aglaia (A. ignea, A. duppereana, A. cucculata, A. 
euphoroides and A. tsangii) showed only ignT1 (dammarenolic acid), dupT1 (aglaiol) and 
cucT1 (niloticin) exhibited selective anti-RSV activity. Time-of-addition studies revealed that 
both ignT1 and dupT1 inhibit RSV replication at a post-entry stage, with ignT1 being 
significantly more potent than dupT1. This post-entry inhibition of viral replication could 
suggest that the inhibitors possibly target the viral replicative enzyme, the RNA polymerase. 
The compound IgnT1 demonstrated favorable cellular safety when compared to reference 
plant derived diterpenoid compound (aphidicolin), which was at the concentration used 
about twice as cytotoxic as ignT1 while demonstrating virtually no anti-RSV activity. 
Besides, ribavarin which is the only currently approved anti-RSV therapeutic agent exhibits 
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much more toxicity resulting from its effect on cellular RNA and DNA polymerases 
(Lafeuillade et al. 2001; Prince 2001; Seetharama and Narayana 2005). Moreover, we also 
observed that methylation of ignT1 resulted in a complete loss of anti-RSV as well as 
cytotoxicity. This remarkable loss of activity could be related to an interaction of the polar 
carboxylic group of dammarenolic acid with a potential target molecule of the virus. In the 
case of the methylated derivative this group is chemically masked and hence the interaction 
is nullified. However, this hypothesis needs to be further confirmed. Thus anti-RSV 
compounds from Aglaia species present useful sources of lead compounds against RSV.  
 
a Concentration of compound (µg/ml) that inhibits RSV infectivity by 50% 
b Concentration of compound (µg/ml) that inhibits viability of target cells (HEp2) by 50% 
c Selectivity index (SI) = TC50/IC50 
d Not determined (ND), because observed activity was not dose-dependent 
Experiments were performed at least thrice 
Reproduced from Esimone et al., 2008 
Table 1. Summary of anti-RSV screening of purified compounds from Aglaia spp 
2.2 Ramalina farinaceae 
Some lichens and lichen-derived substances have been shown to possess anti-viral activities 
(Cohen et al., 1996; Pengsuparp et al., 1995; Neamati et al., 1997). Ramalina farinacea, a lichen 
found to Nigeria but also available in other isolated places, has earlier been shown to 
possess broad anti-retro-viral (including lentiviruses) and anti-adenoviral principles 
(Esimone et al., 2005). Depsides and depsidones have been previously identified as 
antimicrobial active phytochemicals from R. farinaceae (Esimone and Adikwu, 1999; 2002; 
Esimone et al., 1999; 2006). In another related screening studies for active constituents 
against the respiratory syncytial virus, the ethylacetate fraction (ET4) of the plant was 
effective against RSV (IC50= 3.65µg/ml). Mechanistic studies suggested that ET4 targets an 
entry rather than a post-entry step by inhibiting the RSV fusion protein (Esimone et al., 
2009). Further screening exercises and isolation studies are ongoing. 
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a) ignTl (Dammarenolic acid, isolated from the bark of Aglaia ignea) 
b) dupTl (Aglaiol, isolated from the twigs of Agliaia duppereana) 
c) cucTl (Niloticin, isolated from the twigs of Aglaia cucculata) 
Reproduced from Esimone et al., 2008 
Fig. 1. Structual formulae of anti-RSV compounds isolated from Aglaia spp. 
2.3 Anemarrhena asphodeloides 
The rhizomes of Anemarrhena asphodeloides Bunge (Liliaceae) have been used as a traditional 
medicine for anti-diabetic, anti-phlogistic, anti-pyretic, asthma, cough, bronchitis, allergy, 
sedative, diuretic, and anodyne properties in Korea, China, and Japan (Duke et al., 2002). 
Phytochemicals present in this species include xanthones (Pardo-Andreu et al., 2006), 
norlignans (Iida et al., 2000; Park et al., 2003; Lim et al., 2009), and steroidal saponins 
(Nakashima et al., 1993; Sy et al., 2008; Ren et al., 2006; Wang et al., 2010), associated with 
a) 
b) 
c) 
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biological activities such as anti-diabetic (Nakashima et al., 1993), anti-cancer (Sy et al., 2008), 
anti-oxidant (Pardo-Andreu et al., 2006), anti-fungal (Iida et al., 2000; Park et al., 2003), anti-
depressant (Ren et al., 2006), anti-inflammatory (Lim et al., 2009) activity, and 
neuroprotective effects (Wang et al., 2010). Nyasol and its derivatives isolated from the ethyl 
acetate fraction of A. asphodeloides rhizomes had potent RSV inhibitory potential (IC50= 0.39 
to 0.89 µM) (Bae et al., 2007). Thus, these three known phenolic compounds, (-)-(R)-nyasol (= 
4,4’-(1Z,3R)-Penta-1,4-diene-1,3 diyldiphenol; 1), its derivative (-)-(R)-4’-O-methylnyasol (2), 
and broussonin A (3)  isolated from the rhizomes of Anemarrhena asphodeloides were for the 
first time identified as the active principles capable of efficient respiratory syncytial virus 
(RSV) inhibition. Later on, Youn and coworkers (Youn et al., 2011) working with this plant to 
find novel inhibitors of plant origin against the RSV-A2 strain propagated in HEp-2 cells, the 
butanol extract of the rhizomes of A. asphodeloides showed significant inhibitory activity. 
Two steroidal saponins and two xanthone derivatives were isolated from the butanol extract 
of the rhizomes of A. asphodeloides. The structures of the isolated compounds were identified 
as timosaponin A-III (1) (Kawasaki et al., 1963), anemarsaponin B (2) (Dong et al., 1991), 
mangiferin (3) (Qin et al., 2008), and neomangiferin (4) (Qin et al., 2008) using 1D- and 2D- 
NMR techniques such as 1H-13C HSQC and 1H-13C HMBC experiments and by 
comparison with published values. All the isolates (1-4) were evaluated for their ability to 
inhibit RSV. Timosaponin A-III exhibited potential anti-viral activity against the RSV-A2 
strain propagated in HEp-2 cells, with an IC50 of 1.00 μM, which is more potent than the 
positive control, ribavirin (IC50 = 1.15 μM). The remaining compounds anemarsaponin B (2) 
which has a furostanol skeleton, and xanthone glycosides (3 and 4) were inactive (IC50 > 5 
µM). These results suggest that the spirostane skeleton (1) is more active than the furostanol 
structure (2) in the steroidal saponins. They envisaged that further study with more diverse 
compounds is needed to develop these structure-activity relationships.  
2.4 Ligustrum lucidum 
From Ma Shuang-Cheng and coworkers (2001) report is made about activities of six 
secoiridoid glucoside compounds, lucidumoside C, oleoside dimethylester, neonuezhenide, 
oleuropein, ligustroside and lucidumoside A, isolated from the fruits of Ligustrum lucidum 
(Oleaceae). They were examined in vitro for their activities against four strains of pathogenic 
viruses, namely herpes simplex type 1 virus (HSV-1), influenza type A virus (Flu A), 
respiratory syncytial virus (RSV) and parainfluenza type 3 virus (Para 3) with Oleuropein 
being the most potent (IC50 23.4µg/ml) as well as possessing an overall large and best 
therapeutic window (TC50 562.5µg/ml/IC50 23.4µg/ml) comparable to that of ribavirin, an 
approved drug for the treatment of RSV infections in human. Oleuropein is known to 
possess a wide range of biological activities (Ma et al., 2001), one of them being immune-
modulatory activities (He et al., 2001; Saija et al., 1998; Visioli et al., 1995; 1998; ). The 
associated immune effects could enhance its anti-RSV benefit in the biological compartment. 
2.5 Hydroclathrus clathratus and Lobophora variegata 
Products from marine organisms show many interesting activities. Their constituents are 
more novel than those of many terrestrial plants. Seaweeds have long been recognized as 
rich and valuable natural resources of bioactive compounds because of their various 
biological properties (Mayer and Lehmann, 2000). The water-soluble extracts of seaweeds 
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have been shown to exhibit anti-viral activity against a wide spectrum of viruses 
(Witvrouw and de Clercq, 1997). There are more than 200 species of seaweeds in Hong 
Kong coastal waters (Ang, 2005), but research on their anti-viral activity is very limited 
(Zhu et al., 2003). Wang et al. (2008) in their study employed crude water extracts of six 
species of seaweeds Colpomenia sinuosa (Mertens ex Roth), Dictyota dichotoma (Hudson) 
J.V. Lamouroux, Hydroclathrus clathratus, Lobophora variegata (Lamouroux) Womersley ex 
Oliveira, Padina australis Holmes and Sargassum hemiphyllum (Turner) C. Agardh from 
Hong Kong coastal waters were examined for their cellular toxicity and anti-viral 
activities. H. clathratus and L. variegate showed potent anti-RSV activities with EC50 values 
of 25µg/ml and 100µg/ml respectively. 
2.6 Echinacea purpurea 
Several viruses associated with upper respiratory diseases have been shown to stimulate the 
secretion of pro-inflammatory cytokines, including chemokines, sometimes in the absence of 
viral cytopathology. Some plant natural products are known to hold potential of reversing the 
pro-inflammatory effects induced by these viruses, and hence the disease-associated 
symptoms due to their infections (such as cold and flu symptoms of respiratory viruses). One 
such candidate agent is the herbal medicine Echinacea purpurea, which has become one of the 
most popular commercial herbal preparations in North America and Europe (Brevoort, 1998; 
Barnes et al., 2005). There have been numerous reports of immune modulatory properties in 
various preparations derived from different parts of several species of Echinacea (Gertsch et al., 
2004; Barnes et al., 2005; Sharma et al., 2006, 2008; Wang et al., 2006), although the composition 
of these preparations is inconsistent, a fact that has made it difficult to propose a mechanism of 
action (Woelkart and Bauer, 2007). Widely varied anti-viral properties among different 
Echinacea species and component parts have been reported (Hudson et al., 2005; Vimalanathan 
et al., 2005). Thus it is important to carry out research on Echinacea preparations that have been 
standardized and chemically characterized. 
Sharma et al., 2009 evaluated the ability of a standardized preparation of the popular herbal 
medicine Echinacea (Echinaforce®), an ethanol extract of herb and roots of E. purpurea, and 
containing known concentrations of marker compounds) to inhibit the viral induction of 
various cytokines in a line of human bronchial epithelial cells (BEAS-2B), and in two other 
human cell lines. They found Echinacea (Echinaforce® to inhibit respiratory syncytial virus 
(RSV)-induced IL-6 and IL-8 (CXCL8) secretion, in addition to several other chemokines. In 
every case however Echinacea inhibited this induction. The Echinacea preparation also 
showed substantial virucidal activity against RSV (MIC 2.5µg/ml) indicating the multi-
functional potential of the herb. These results support the concept that certain Echinacea 
preparations can alleviate “cold and flu” symptoms, and possibly other respiratory 
disorders, by inhibiting viral growth and the secretion of pro-inflammatory cytokines. 
2.7 Dysoxylum gaudichaudianum 
The medicinal plant Dysoxylum gaudichaudianum Miq. (Meliaceae) is local to Papua New 
Guinea. The leaves and bark are used as a medicine by the indigenous people for treating 
rigid limbs, facial distortion in children, lumps under the skin, and other irritations, and as a 
remedy for sexually transmitted diseases (Weiner, 1984). They are also reportedly used as a 
remedy for fish poisoning and for convulsions (Cambie and Ash, 1994). A liquid drink made 
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by adding boiling water to the chopped leaves is considered to be a cure for most aches and 
pains (Parham, 1943) and is used for lung hemorrhage (Donald et al., 1975). Anti-RSV agents 
from Dysoxylum gaudichaudianum were described by Chen et al., 2007. Both aqueous (water 
or 1:1 water-2-propanol) and organic (1:1 methylene chloride-2-propanol) extracts of D. 
gaudichaudianum bark showed inhibitory activity against the RSV strain A2 in CPE inhibition 
and plaque reduction assays. Using respiratory syncytial viral CPE inhibition and plaque 
reduction assays to guide bioactivity-directed fractionation, the active fraction was found to 
be present in the more lipophilic phase, following liquid-liquid partition (chloroform/ 
aqueous ethanol). Reversed-phase chromatography of the organic extract led to the 
complete separation and isolation of four structurally related new compounds. The four 
new compounds, belonging to the tetranortriterpenoid family, named dysoxylins A-D, 
which were found to exhibit potent anti-viral activity against RSV. NMR spectroscopic 
analysis of this fraction indicated the presence of complex structures. These new compounds 
showed significant anti-RSV activity in both the cytopathic effect (CPE) inhibition and 
plaque reduction assays (1 to 4 µg/ml). 
2.8 Caesalpinia minax 
Caesalpinia minax Hance, a member of the Caesalpinia genus, is a prickly shrub growing in 
the tropics and subtropics. The seeds of this plant, which is called ‘ku-shi-lian’, have long 
been used as Chinese folk medicine for the treatment of common cold, fever and 
dysentery (Jiangsu New Medical College, 1977). Jiang et al. (2001) working with the 
chloroform fraction of the ethanol (95%) extract of the seeds was found to show in vitro 
anti-RSV activity, and a subsequent bioassay-guided study led to the isolation of a novel 
rearranged vouacapane diterpenoid possessing a new carbon skeleton, now designated 
spirocaesalmin. Spirocaesalmin, a novel rearranged vouacapane diterpenoid that exhibits 
significant activity against respiratory syncytial virus, possesses a new carbon skeleton 
with a spiro-CD ring system. Spirocaesalmin has been found to exhibit significant activity 
against respiratory syncytial virus (IC50 = 19.5 ± 1.5 μg mL, TC50 = 126.9 ± 2.0 μg ml and SI 
= 6.5) in cell culture, and the corresponding values for the positive control (ribavirin) are 
3.6 ± 0.2 μg ml, 62.5 ± 1.9 μg ml and 17.4, respectively. Thus isolation of spirocaesalmin 
with a novel spiro-heterocyclic ring skeleton and the first bioassay against RSV in the 
family of vouacapane diterpenoids provide a potentially useful lead to the search for anti-
viral drugs. 
2.9 Lithraea molleoides, Polygonum punctatum and Myrcianthes cisplatensis 
The search for anti-viral agents against RSV among the province of Entre Rı´os in Argentina 
has led to the discovery of plants which are expected to lead to identification of promising hits. 
These plants include Lithraea molleoides, Polygonum punctatum and Myrcianthes cisplatensis. 
The trees of the genus Lithraea Hook. et Arn. (Anacardiaceae) are traditionally known for their 
irritating effects, especially among woodcutters and carpenters. Lithraea molleoides (Vell.) 
Engler called ‘a´rbol malo’ (evil tree), common name ‘chichita’, or ‘molle de Co´rdoba’, 
produces discomfort, drowsiness, lack of strength, rash and swelling in exposed parts of the 
body to anyone approaching to the tree. A myth exists about the healing powers of this tree, 
which also provides good quality timber and has tanning and dyeing bark (Munoz, 1990). 
Fruits have a volatile oil believed to cause, according to the ancient tradition, very strong and 
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disturbing irritation of the eyes and the skin (Storni, 1994). In the northwest of Argentina the 
fruits are used to make an alcoholic drink. The infusion of the leaves and fruits is said to be 
diuretic and stomachic (Cabrera, 1938). A decoction of the twigs is useful for breathing and 
digestive diseases (Ratera and Ratera, 1980). The tincture and the decoction are a good remedy 
for cough, bronchitis and phlegm. They are also hemostatic, stomachic, tonic and refreshing 
(Burgstaller Chiriani, 1974) and are used for arthritis (Martius, 1843).  
The genus Polygonum L. is rich in medicinal species in the old as well as the new world. 
All of them are rich in tannins and some are occasionally used as foods (Lewis and Elvis-
Lewis, 1977). Polygonum punctatum Elliot (Polygonaceae) is one of the most widely spread 
species of the genus in the province of Entre Rı´os, and is found in different habitats. It is 
considered poisonous to man and ocasionally fatal to livestock (Lewis and Elvis-Lewis, 
1977). The acrid juice can cause both internal and external inflammation. It should be used 
only in professionally-made preparations and with medical supervision. It has astringent, 
diaphoretic, diuretic and rubefacient properties. A cold extract can be applied to skin 
problems, scabies, and hemorrhoids and as a gargle for toothache and problems in the 
larynx. The juice, pure or thinned with water, is effective in drawing pus out of sores 
(Lust, 1974). Infusion of the whole plant of Polygonum punctatum Elliot var., Aquatile 
(Martins) Fasset, also called ‘erva do bicho’ or ‘caa-tai’, ‘ajicillo’, is used in traditional 
medicine by the Toba indians of the northeastern region of Argentina, as a disinfectant 
and vulnerary in lavages of pimples, wounds and rash and as an antihemorrhoidal 
(Martı´nez Crovetto, 1964, 1965, 1981). 
Many species of Argentine Myrtaceae are recognized as astringents and they are often mixed 
to potentiate their effects. The infusion of the leaves and the wood decoction of Myrcianthes 
cisplatensis (Camb.) Berg. (Myrtaceae) ‘lapachillo’, ‘guayabo colorado’ or ‘palo pelado’, is 
claimed to be astringent, tonic, stimulant, febrifuge and diuretic, and especially useful to 
wash and heal ulcers (Gonza´lez Torres, 1992). It is also a good remedy for lung and 
bronchial affections (Font Quer, 1988). It is a very common tree in the river-banks of the 
province of Entre Rı´os, easily recognizable by its clear bark and the strong odor of its 
leaves,which have contributed for its popularity.  
The anti-RSV activities of L. molleoides, P. punctatum and M. cisplatensis extracts were 
reported by Kott et al., 1998. They reported ED50 values ranging from 78 to 120µg/ml. Their 
preliminary work therefore validated the continued traditional utilization of these plants as 
anti-viral remedies especially against RSV, and concluded on the need to further purify to 
isolate active compounds for further developments as anti-RSV agents.  
2.10 Anti-RSV herbs commonly used in traditional Chinese medicines 
Ma et al. (2002) described about 44 Chinese herbs commonly used in treatment of RSV 
disease. Traditional Chinese medicinal herbs have long been used as remedies against 
infectious diseases in China. Traditional medicines in the form of hot water extracts have 
been used orally for the treatment of various diseases. It is very likely that hot water extracts 
of some herbs would exhibit direct anti-viral activity in vitro at the concentration used for 
therapy. In this study Ma and coworkers assayed 44 medicinal herbs, which are currently 
used for the treatment of respiratory tract infectious diseases in China, to test anti-viral 
activities against RSV in vitro by cytopathic effect assay. The extracts of Sophora flaescens Ait. 
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and Scutellaria baicalensis Georgi with anti-viral properties were further investigated to 
identify their anti-viral components against RSV. 
Aqueous extracts from these traditional Chinese medicines were also studied to detect 
anti-viral activity against RSV. Of all the 44 herbs tested, 41 showed anti-RSV activities 
with the following 25 herbs showing the strongest potency (IC50= 6.3 to 52.1µg/ml) and 
also largest selective index (SI= 4.0 to 32.1): Andrographis paniculata, Artemisia capillaries, 
Bupleurum chinense, Callicarpa nudiflora, Dendranthema morifolium, Forsythia suspensa, 
Ipomoea cairica, Gardenia jasminoides, Isatis indigotica, Lonicera japonica, Paeonia suffruticosa, 
Patrinia _illosa, Perilla frutescens, Phragmites communis, Platycodon grandiflorum, Polygonum 
cuspidatum, Polygonum multiflorum, Prunella _ulgaris, Pueraria lobata, Sarcandra glabra, 
Schizonepeta tenuifolia, Scutellaria baicalensis, Selaginella sinensis, Sophora flaescens and 
Tinospora capillipes. All of these traditional Chinese medicines extracts were considered 
active, and of interest for further investigation. Further purification of 2 of the herbs 
(Sophora flavescens and Scutellaria baicalensis) led to the isolation of potent anti-viral 
compounds. Sophora flaescens and of Scutellaria baicalensis were further investigated and 
led to the identification from these two herbs anagyrine, oxymatrine, sophoranol, 
wogonin, and oroxylin A as the most potent anti-viral compounds against RSV; their IC50 
values ranged from 7.4 to 14.5 µg/ml.  
2.11 Narcissus tazetta, Youngia japonica and Flos lonicerae 
Ooi et al., 2010 investigated the inhibitory effect of a novel mannose-binding lectin NTL 
isolated, purified and cloned from the bulbs of the Chinese daffodil, Narcissus tazetta var. 
chinensis, against human RSV, and various strains of influenza A (H1N1, H3N2, H5N1) and 
influenza B viruses. NTL was obtained after FPLC-gel filtration followed by desalting with a 
PD-10 column, and its purity was analysed by SDS-PAGE. It was determined to have a 
molecular mass of about 26 kDa by gel filtration and 13 kDa by SDS–PAGE. NTL is 
suggested to be a mannose-binding homodimer with two identical subunits of about 13 
kDa. Molecular cloning revealed that the deduced amino acid sequence of the full-length 
cDNA encoding NTL contained a mature polypeptide consisting of 105 amino acids and a 
C-terminal peptide extension beyond the C-terminal amino acids Thr-Gly. NTL could 
effectively inhibit RSV-induced plaque formation (IC50= 2.30 µg/ml). Its cytotoxicity against 
HEp-2 cells was low (CC50= 325.4 µg/ml) and thus it had a high SI value of 141.36.   
In another related earlier study, Ooi together with other investigators (Ooi et al., 2006) 
reported the anti-RSV activity of the ethanol extract of a biannual medicinal herb, Youngia 
japonica (commonly known as Oriental hawk’s beard). Two potent anti-RSV compounds 
namely 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid, were subsequently purified 
and chemically characterized from the ethanol extract of Youngia japonica. The two 
dicaffeoylquinic acids exhibited prominent anti-RSV with an IC50 of 0.5µg/ml and there was 
no sign of cytotoxicity up to 100µg/ml concentration.  
CJ 4-16-4 is a promising potent inhibitor of RSV isolated from Flos lonicerae using bioassay-
guided fractionation. The drug inhibits of RSV in Hep-2 cells maintained in tissue culture at a 
very low concentration (~0.07 μM) with cell toxicity >400 μM (SI > 5880). In a cotton rat model 
of RSV infection, the drug was able to reduce viral titers by ~1 log at dose 12.5 and 25 
mg/kg/day, and by >2 log at 100 mg/kg/day. This antiviral activity was specific as influenza 
A and B and herpes simplex 1 and 2 viruses were not inhibited (Ojwang et al., 2005). 
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Scientific name of Plant  
Promising isolated 
compounds
References 
Aglaia ignea Dammarenolic acid Esimone et al., 2008 
Aglaia duppereana Aglaiol Esimone et al., 2008 
Aglaia cucculata Niloticin Esimone et al., 2008 
Anemarrhena asphodeloides 
(-)-(R)-Nyasol*
(-)-(R)-4’-O-methylnyasol* 
Broussonin A* 
timosaponin A-III*
Bae et al., 2007; Youn  
et al., 2011; Kawasaki  
et al., 1963 
Dysoxylum gaudichaudianum Dysoxylins A-D* Chen et al., 2007 
Sophora flavescens  
Allmatrine
Anagyrine 
Cytisine 
Isomatrine 
Matrine 
N-methylcytisine 
Oxymatrine 
Oxysophocarpine 
Sophocarpine 
Sophoranol 
Sophoridine
Ma et al., 2002 
Scutellaria baicalensis 
Wogonin
Oroxylin A 
Baicalein 
Scutellarein 
Baicalin
Ma et al., 2002 
Caesalpinia minax Spirocaesalmin Jiang et al., 2001 
Ligustrum lucidum Oleuropein Ma et al., 2001 
Narcissus tazetta NTL Ooi et al., 2010 
Youngia  japonica Dicaffeoylquinic acids Ooi et al., 2006 
Flos  lonicerae CJ 4-16-4 Ojwang et al., 2005 
Key: Promising isolated compounds determined on the basis of S.I index ≥ 4 
*SI index not reported 
Table 2. Promising anti-RSV compounds isolated from phytomedicines 
3. Potential usefulness of anti-RSV compounds and phyto-constituents 
harnessed from phytomedicines in the treatment and control of RSV 
infection and disease 
Complementary and alternative medicines have been used effectively by humans over 
several centuries for treating various diseases and can therefore be effectively employed to 
target the host response during RSV infection. Currently, no effective vaccine or therapeutic 
drug is available against RSV. Although ribavirin, a broad-spectrum anti-viral agent, is 
being marketed under approval, its clinical benefits are small and limited coupled, with the 
high cost and toxicity associated with it (Kneyber et al. 2000; Lafeuillade et al. 2001; 
Seetharama and Narayana 2005). New therapies designed to combat moderate to severe 
RSV infection and disease are clearly needed. Anti-RSV compounds from phytomedicines 
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could fill this gap. Although there have been several reports on natural anti-RSV agents, 
including some flavans (Li et al., 2006), caffeoylquinic acid (Li et al., 2005), and some 
alkaloids such as anagyrine, oxymatrine, and sophoranol (Ma et al., 2002). However, more 
anti-RSV drug candidates from phytomedicines need to be discovered for future 
development. A number of synthetic organic compounds have also received attention as 
anti-RSV agents however some are too cytotoxic to develop as clinically useful agents 
(Golankiewicz et al., 1995). Given the foregoing therefore, the potential usefulness of 
medicinal plants – either as suitable sources for the development of potent anti-viral anti-
RSV agents or as effective tools in alternative medical practice, cannot be in question. 
Medicinal plants remain sources of cost-effective and accessible anti-viral remedies for use 
in developing and developed countries (Chen et al., 2008; Cowan, 1999; De Clercq, 1995; 
Jassim and Naji, 2003; Vlietinck and Vanden, 1991; Williams, 2001). They also could reduce 
time to be spent synthesizing new molecules. Moreover, reports of some strains of RSV 
developing resistance to currently administered therapeutic agents such as Ribavirin further 
underscore the need for effort for the development of new and more effective anti-viral 
agents to be undertaken. Finally, the screening of plants as a possible source of anti-viral in 
the ethnopharmacological approach enhances the probability of identifying new bioactive 
plant compounds (Vlietinck and Vanden, 1991; Baker et al., 1995). It is therefore hoped that 
anti-viral compounds from phytomedicines against RSV would greatly serve diverse 
usefulness in the management of RSV infection and disease. 
4. Conclusion 
Historically, plants have provided a source of inspiration for novel drug compounds, as 
plant derived medicines have made large contributions to human health and well-being. 
Their role is twofold in the development of new drugs: first, they may become the base for 
the development of a medicine, a natural blueprint for the development of new drugs, or; 
second: a phytomedicine to be used for the treatment of disease. There are numerous 
illustrations of plant derived drugs. It is estimated that today, plant materials are present in, 
or have provided the models for at least 50% Western drugs (Schuster, 2001). Many 
commercially proven drugs used in modern medicine were initially used in crude form in 
traditional or folk healing practices, or for other purposes that suggested potentially useful 
biological activity. The primary benefits of using plant derived medicines are that they are 
relatively safer than synthetic alternatives, offering profound therapeutic benefits and more 
affordable treatment. 
Currently, investigations into the anti-RSV virus activities of numerous plant species are 
ongoing. A sense of urgency accompanies the search as the pace of species extinction 
continues. More of these compounds should be subjected to animal and human studies to 
determine their effectiveness in whole-organism systems, including in particular toxicity 
studies. It would be advantageous to standardize methods of extraction and in vitro testing 
so that the search could be more systematic and interpretation of results would be 
facilitated. Also, alternative mechanisms of infection prevention and treatment should be 
included in initial activity screenings. Disruption of adhesion is one example of an anti-
infection activity not commonly screened for currently. Attention to these issues could usher 
in a badly needed new era of chemotherapeutic treatment of infection by using plant-
derived principles. 
www.intechopen.com
 
Anti-Respiratory Syncytial Virus Agents from Phytomedicine 
 
191 
5. References 
Adegbola RA, Falade AG, Sam BE et al. (1994) The etiology of pneumonia in malnourished 
and well-nourished Gambian children. Pediatric Infectious Disease Journal 13, 975–
982. 
Ang PO (2005) Studies of Marine Algae in Hong Kong. In: Critichley AT, Ohno M, Largo D. 
(Eds.), World Seaweed Resources. ETI Information Services Ltd., Wokingham, 
Berkshire, UK, Part 3. 04. 
Bae G, Yu JR, Lee J, Chang J, Seo EK (2007). Identification of nyasol and structurally related 
compounds as the active principles from Anemarrhena asphodeloides against 
respiratory syncytial virus (RSV). Chem. Biodivers., 4: 2231-2235. 
Baker, T., Borris, R., Carte, B., Cragg, G., Gupta, M., Iwu, M., Madulid, D., Tyler, V., 1995. 
Natural product drug discovery and development: new perspectives on international 
collaboration. Journal of Natural Products 58, 1325–1357. 
Barnes J, Anderson LA, Gibbons S, Phillipson JD (2005) Echinacea species (Echinacea 
angustifolia (DC.) Hell. Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) 
Moench: a review of their chemistry, pharmacology and clinical properties. J. 
Pharm. Pharmacol. 57: 929-954. 
Berkovich, S. 1964. Acute respiratory illness in the premature nursery associated with 
respiratory syncytial virus infections. Pediatrics 34:753–760. 
Bohnenstengel FI, Steube KG, Meyer C, Nugroho BW, Hung PD, Kiet LC, Proksch P (1999) 
Structure activity relationships of antiproliferative rocaglamide derivatives from 
Aglaia species (Meliaceae). Z Naturforsch. 54: 55–60. 
Brevoort P (1998) The booming US botanical market. HerbalGram 44: 33–48. 
Burgstaller Chiriani CH (1974) La vuelta a los vegetales, 5th edn. La Prensa Me´dica Argentina, 
Buenos Aires. 
Cambie RC, Ash J (1994) Fijian Medicinal Plants; CSIRO: Collingwood, Victoria, Australia. 
Chen JL, Kernan MR, Jolad SD, Stoddart CA, Bogan M, Cooper R (2007) Dysoxylins A-D, 
Tetranortriterpenoids with Potent Anti-RSV Activity from Dysoxylum 
gaudichaudianum. J. Nat. Prod. 70: 312-315. 
Cheng HY, Huang HH, Yang CM, Lin LT, Lin CC (2008) The in vitro anti-herpes simplex 
virus type-1 and type-2 activity of Long Dan Xie Gan Tan, a prescription of 
traditional Chinese medicine. Chemotherapy. 54: 77-83. 
Cohen PA, Hudson JB, Towers GH (1996) Anti-viral activities of anthraquinones, 
bianthrones and hypericin derivatives from lichens. Experientia. 52: 180-183. 
Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313–1351. 
In B. N. Fields (ed.), Fields virology. Raven Press, New York, N.Y. 
Cowan MM (1999) Plant products as antimicrobial agents. Clin Microbiol Rev. 12: 564-
582.De Clercq E (1995) Anti-viral therapy for human immunodeficiency virus 
infections. Clin Microbiol. Rev. 8: 200-239. 
Donald C, Artney L, Innes H (1975) Medicines of the Maori; Collins: Auckland, pp 1-6. 
Dong J, Han G (1991). A new active steroidal saponin from Anemarrhena asphodeloides. Planta 
Med., 57: 460-462. 
Dowell, S. F., L. J. Anderson, H. E. Gary, Jr., D. D. Erdman, J. F. Plouffe, T. M. File, Jr., B. J. 
Marston, and R. F. Breiman (1996) Respiratory syncytial virus is an important cause 
of community-acquired lower respiratory infection among hospitalized adults. J. 
Infect. Dis. 174:456–462.  
www.intechopen.com
 
Human Respiratory Syncytial Virus Infection 
 
192 
Duke JA, Bogenschutz-Godwin MJ, duCellier J, Duke PAK (2002). Handbook of Medicinal 
Herbs, 2th ed, CRC Press, New York, p. 27. 
Esimone CO, Adikwu MU (1999) Antimicrobial activity and cytotoxicity of Ramalina 
farinacea. Fitoterapia. 70: 428-431. 
Esimone CO, Adikwu MU (2002) Susceptibility of some clinical isolates of Staphylococcus 
aureus to bioactive column fractions from the lichen Ramalina farinacea (L) Ach. 
Phytother Res. 16: 494-496. 
Esimone CO, Adikwu MU, Ebi GC, Anaga A, Njoku C (1999) Physicochemical 
evaluationsand bioactive properties of column fractions from the lichen Ramalina 
farinacea (L) Ach. Boll Chim Farm. 138: 19-25. 
Esimone CO, Grunwald T, Nworu CS, Kuate S, Proksch P, Uberla K (2009) Broad Spectrum 
Anti-viral Fractions from the Lichen Ramalina farinacea (L.) Ach. Chemotherapy. 
55:119-126. 
Esimone CO, Nwodo NJ, Iroha, IR and Ogbuefi NR (2006) Antifungal screening of the 
methanolic extract of the Lichen Ramalina farinacea (L) Ach. Afric J Pharm Res Dev. 
2: 1-6. 
Esimone, C. O., Eck, G., Duong, T. N., Uberla, K., Proksch, P., Grunwald, T. 2008. 
Potential anti-respiratory syncytial virus lead compounds from Aglaia species. 
Pharmazie. 63: 1-6. 
Falsey AR, Patricia AH, Maria AF, Christopher C, and Walsh EE. 2005. Respiratory 
Syncytial Virus Infection in Elderly and High-Risk Adults. N. Engl. J. Med. 352: 
1749-1759.  
Falsey, A. R. and E. E. Walsh. 1998. Relationship of serum antibody to risk of respiratory 
syncytial virus infection in elderly adults. J. Infect. Dis. 177: 463–466. 
Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B.  
Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the 
institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 
40:115–119. 
Font Quer, P., 1988. Plantas Medicinales. El Diosco´ rides Renovado. Labor, Barcelona. 
Fouillard, L., L. Mouthon, J. P. Laporte, F. Isnard, J. Stachowiak, M. Aoudjhane, J. C. 
Lucet, M. Wolf, F. Bricourt, L. Douay, M. Lopez, C. Marche, A. Najman, and N. C. 
Gorin. 1992. Severe respiratory syncytial virus pneumonia after autologous bone 
marrow transplantation: a report of three cases and review. Bone Marrow 
Transplant. 9:97–100. 
Gautam R, Saklani A, Jachak SM (2007) Indian medicinal plants as a source of 
antimycobacterial agents. J Ethnopharmacol. 110: 200-34. 
Golankiewicz B, Januszczyk P, Ikeda S, Balzarini J, DeClercq E (1995) Synthesis and anti-viral 
activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9 
dideazapurine) derivatives. J. Med. Chem. 38: 3558-3565. 
Gonza´lez Torres, D.M., 1992. Cata´logo de Plantas Medicinales usadas en Paraguay. 
Asuncio´n.Groothuis, J. R., K. M. Gutierrez, and B. A. Lauer. 1988. Respiratory 
syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 
82:199–203. 
Harvey AL (2008) Natural products in drug discovery. Drug Discov Today. 13: 894-901. 
www.intechopen.com
 
Anti-Respiratory Syncytial Virus Agents from Phytomedicine 
 
193 
He ZD, But PPH, Chan TWD, Dong H, Xu HX, Lau CP, Sun HD (2001) Antioxidative 
glucosides from the fruits of Ligustrum lucidum. Chem. Pharm. Bull., 49, 780—784 
(2001). 
Hudson J, Vimalanathan S, Kang L, Treyvaud Amiguet V, Livesey J, Arnason JT (2005) 
Characterization of anti-viral activities in Echinacea root preparations. Pharmacol. 
Biol. 43: 790-796. 
Iida Y, Oh KB, Saito M, Matsuoka H, Kurata H (2000). In vitro synergism between nyasol, an 
active compound isolated from Anemarrhena asphodeloides, and azole agents against 
Candida albicans. Planta Med., 66: 435-438. 
Jassim SAA, Naji MA (2003) Novel anti-viral agents: a medicinal plant perspective. J Appl 
Microbiol. 95: 412-27. 
Jiang R, Ma S, But PP, Mak TCW (2001) Isolation and characterization of spirocaesalmin, a 
novel rearranged vouacapane diterpenoid from Caesalpinia minax Hance. J. Chem. 
Soc., Perkin Trans. 1. 2920-2923. 
Jiangsu New Medical College (1977) Dictionary of Chinese Traditional Medicine, Shanghai 
People’s Publishing House, P. R. China, p. 1289. 
Kawasaki T, Yamauchi T (1963). Saponins of Timo (Anemarrhenae Rhizoma). II. Structure of 
timosaponin A-III. Chem. Pharm. Bull., 11: 1221-1224. 
Kneyber MCJ, Moll HA, de Groot R (2000) Treatment and prevention of respiratory syncytial 
virus infection. Eur. J. Pediatr. 159 (6): 399-411. 
Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura V, Tenbusch M, Überla K and 
Grunwald T. 2009. Protective Efficacy and Immunogenicity of an Adenoviral Vector 
Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus. 83 
(23): 12601-12610. 
Kott V, Barbini L, Cruanes M, et al. (1999) Anti-viral activity in Argentine medicinal plants. J. 
Ethnopharmacol. 64: 79-84. 
Lafeuillade A, Hattinger G, Chadapaud S (2001) Increased mitochondrial toxicity with 
ribavirin in HIV/HCV coinfection. Lancet 357: 280–281. 
Langley GF  and Anderson LJ. 2011.  Epidemiology and Prevention of Respiratory Syncytial 
Virus Infections Among Infants and Young Children. Pediatr.  Infect.  Dis. J. 30: 
510–517. 
Lewis WH, Elvis-Lewis MP (1977) Medical Botany. John Wiley and Sons, New York. 
Li Y, But PP, Ooi VE (2005) Anti-viral Res. 68: 1. 
Li Y, Leung K, Yao F, Ooi LS, Ooi VE (2006) J. Nat. Prod. 69: 833. 
Lipipun V, Kurokawa M, Suttisri R, Taweechotipatr P, Pramyothin P, Hattori M, Shiraki K 
(2003) Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 
infection in vitro and in vivo. Antivir Res 60 : 175–180. 
Lust J (1974) The Herb Book. Bantam Books, New York. 
Ma S, Du J, But PP, Deng X, Zhang Y, Ooi VE, Xu H, Lee SH, Lee SF (2002) Anti-viral Chinese 
medicinal herbs against respiratory syncytial virus. Journal of Ethnopharmacology. 79: 
205-211. 
Ma S, He Z, DENG X, But PP, Ooi VE, Xu H, Lee SH, Lee S (2001) In Vitro Evaluation of 
Secoiridoid Glucosides from the Fruits of Ligustrum lucidum as Antiviral Agents. Chem. 
Pharm. Bull. 49 (11): 1471-1473. 
www.intechopen.com
 
Human Respiratory Syncytial Virus Infection 
 
194 
MacDonald, N. E., C. B. Hall, S. C. Suffin, C. Alexson, P. J. Harris, and J. A. Manning. 1982. 
Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. 
J. Med. 307:397–400. 
Martı´nez Crovetto R (1964) Estudios Etnobota´nicos I. Bonplandia. 4: 270-333. 
Martı´nez Crovetto, R., 1965. Estudios etnobota´nicos II. Nombres de plantas y su utilidad 
segu´n los indios tobas del estedel Chaco. Bonplandia. 4: 279-333. 
Martı´nez Crovetto, R., 1981. Las plantas utilizadas en medicina popular en el Noroeste de 
Corrientes. Repu´ blica Argentina. Fundacio´n M. Lillo. Tucuma´n, Argentina. 
Martin W.Weber1, E. Kim Mulholland and Brian M. Greenwood. (1998) Respiratory syncytial 
virus infection in tropical and developing countries. Tropical Medicine and 
International Health. 3 (4): 268–280.  
Martius FP (1843 Systema Material Madicae Vegetabilis Brasiliensis. Fleischer, Leipzig and 
Beck, Vienna. 
Mayer AMS, Lehmann VKB, (2000) Marine pharmacology in 1998: marine compounds with 
antibacterial, anticoagulant, antifungal, anti-inflammatory, anthelmintic, antiplatelet, 
antiprotozoal, and anti-viral activities; with actions on the cardiovascular, endocrine, 
immune, and nervous systems, and other miscellaneous mechanism of action. The 
Pharmacologist. 42: 62-69. 
Munoz J de D (1990) Usos principales de la especies de Anacardiaceae, particularmente de 
Paraguay. Candollea. 45: 671-680. 
Nakashima N, Kimura I, Kimura M (1993). Isolation of pseudoprototimosaponin AIII from 
rhizomes of Anemarrhena asphodeloides and its hypoglycemic activity in 
streptozotocin-induced diabetic mice. J. Nat. Prod., 56: 345-350. 
Neamati N, Hong H, Mazumder A., Wang S, Sunder S, Nicklaus MC, Milne GW, Proksa 
B, Pommier Y (1997) Depsides and depsidones as inhibitors of HIV-1 integrase: 
discovery of novel inhibitors through 3D database searching. J Med Chem. 40: 
942-951. 
Nwankwo MU, Okuonghae HO, Currier G and Schuit KE (1994) Respiratory syncytial virus in 
malnourished children. Annals of Tropical Paediatrics 14, 125–130. 
Ojwang JO, Wang Y, Wyde PR, Fischer NH, Schuehly W, Appleman JR, Hinds S, Shimasaki 
CD. 2005.  A novel inhibitor of respiratory syncytial virus isolated from 
ethnobotanicals. Antiviral research. 68 (3): 163-172. 
Ooi LSM, Ho W, Ngai KLK, Tian L, Chan PKS, Sun SSM, Ooi VEC. 2010. Narcissus tazetta 
lectin shows strong inhibitory effects against respiratory syncytial virus, infl uenza 
A (H1N1, H3N2, H5N1) and B viruses. J. Biosci. 35(1): 95–103. 
Ooi LSM, Wang H, He Z, Ooi VEC. 2006. Antiviral activities of purified compounds from 
Youngia japonica (L.) DC (Asteraceae, Compositae). Journal of Ethnopharmacology. 
106: 187–191 
Pannell CM (1992) A taxonomic monograph of the genus Aglaia Lour. (Meliaceae). Kew 
Bulletin Additional Series XVI, Royal Botanic Gardens, Kew. HMSO, London, p. 
1–379. 
Pardo-Andreu GL, Sanchez-Baldoquin C, Avila-Gonzalez R, Delgado R, Naal Z, Curti C 
(2006). Fe(III) improves antioxidant and cytoprotecting activities of mangiferin. Eur. J. 
Pharmacol., 547: 31-36. 
Parham HBR (1943) Polynesian Soc. Mem. 16, 1-4. 
www.intechopen.com
 
Anti-Respiratory Syncytial Virus Agents from Phytomedicine 
 
195 
Park HJ, Lee JY, Moon SS, Hwang BK (2003). Isolation and antioomycete activity of nyasol 
from Anemarrhena asphodeloides rhizomes. Phytochem., 64: 997-1001. 
Pengsuparp T, Cai L, Constant H, Fong HH, Lin LZ, Kinghorn AD, Pezzuto JM, Cordell 
GA, Ingolfsdottir K, Wagner H, Hughes SH (1995) Mechanistic evaluation of new 
plant-derived compounds that inhibit HIV-1 reverse transcriptase. J Nat Prod. 58: 
1024-1031. 
Perry LM (1980) Medicinal plants of East and Southeast Asia. MIT Press, Cambridge, MA. 
Poehland BL, Carte BK, Francis TA, Hyland LJ, Allaudeen HS, Troupe N (1987) In vitro anti-
viral activity of dammar resin triterpenoids. J Nat Prod 50: 706–713. 
Preceding Mitochondria-Mediated Apoptosis in HeLa Cancer Cells. Cancer Res., 68: 10229-
10237. 
Prince GA (2001) An update on respiratory syncytial virus anti-viral agents. Expert Opin 
Investig Drugs 10: 297–308. 
Qin L, Han T, Zhang Q, Cao D, Nian H, Rahman K, Zheng H (2008). Antiosteoporotic 
chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J. 
Ethnopharmacol., 118: 271- 279. 
Ratera E, Ratera M (1980) Plantas de la flora argentina empleadas en medicina popular. 
Edicio´n hemisferio sur, Buenos Aires. 
Ren LX, Luo YF, Li X, Zuo DY, Wu YL (2006). Antidepressant-like effects of 
sarsasapogenin from Anemarrhena asphodeloides BUNGE (Liliaceae). Biol. Pharm. 
Bull., 29: 2304-2306. 
Saija A, Trombetta D, Tomaino A, Lo Cascio R, Princi P, Uccella N, Bonina F, Castelli F (1998) 
In vitro evaluation of the antioxidant activity and biomembrane interaction of the 
plant phenols Oleuropein and hydroxytyrosoI. Int. J. Pharmaceut., 166: 123-133. 
Schuster BG (2001) A new integrated program for natural product development and the value 
of an ethnomedical approach. J. Altern. Complement Med. 7 (Suppl 1): S61-72. 
Seetharama RKS, Narayana K (2005) In vivo chromosome damaging effects of an inosine 
monophosphate dehydrogenase inhibitor: Ribavirin in mice. Indian J Pharmacol 
37: 90–95. 
Semple SJ, Reynolds GD, O’Leary GD, Flower RLP (1998) Screening of Australian medicinal 
plants for anti-viral activity. J. Ethnopharmacol. 60: 163-72. 
Sharma M, Anderson SA, Schoop R, Hudson JB (2009) Induction of multiple pro-inflammatory 
cytokines by respiratory viruses and reversal by standardized Echinacea, a potent 
anti-viral herbal extract. Anti-viral Research. 83: 165–170. 
Sharma M, Arnason JT, Burt A, Hudson,JB (2006) Echinacea extracts modulate the pattern of 
chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial 
cells. Phytother. Res. 20: 147-152. 
Sharma M, Schoop R, Hudson JB (2008) Echinacea as an anti-inflammatory agent: the influence 
of physiologically relevant parameters. Phytother. Res. doi:10.1002/ptr.2714. 
Sindambiwe JB, Calomme M, Cos P, et al. (1999) Screening of seven selected Rwandan 
medicinale plants for antimicrobial and anti-viral activities. J. Ethnopharmacol. 
65: 71-7. 
Storni J (1994) Hortus guaranensis. Flora. Universidad Nacional de Tucuma´n. Publicacio´n 
Nu´mero, 354.Sy LK, Yan SC, Lok CN, Man RYK, Che CM (2008). Timosaponin A-III 
Induces Autophagy  
www.intechopen.com
 
Human Respiratory Syncytial Virus Infection 
 
196 
Tregoning JS, Schwarze J. 2010. Respiratory viral infections in infancy: causes, clinical 
symptoms, virology, and immunology. Clinical Microbiology Reviews 23: 74–98. 
Tucuman TH, Shihman CR, Smith K (1989) Isolation, purification and partial characterization 
of prunellin, an anti-HIV component from aqueous extracts of Prunella vulgaris. 
Antiviral Research 11, 263-274. 
Vimalanathan S, Kang L, Treyvaud Amiguet V, Livesey J, Arnason JT, Hudson J (2005) 
Echinacea purpurea aerial parts contain multiple anti-viral compounds. Pharmacol. 
Biol. 43: 740-745. 
Visioli F, Bellasta S, Galli C (1998) Oleuropein, the bitter principle of olives, enhances nitric 
oxide production bymousemacrophages. Life Sci. 62: 541-546.  
Visioli F, Bellomo G, Galli C (1998) Free radical-scavenging properties of olive oil 
polyphenol. Biochem. Biophys. Res. Commun. 247 (1): 60-4. 
Visioli F, Bellomo G, Montedoro GF, Galli C (1995) Low density lipoprotein oxidation is 
inhibited in vitro by olive oil constituents. Atherosclerosis. 117 (1): 25-32. 
Vlietinck A, Vanden BD (1991) Can ethnopharmacology contribute to the development of anti-
viral drugs. Journal of Ethnopharmacology. 32: 141-153. 
Wang CY, Chiao MT, Yen PJ, Huang WC, Hou CC, Chien SC, Yeh KC, Yang WC, Shyur LF, 
Yang NS (2006) Modulatory effects of Echinacea purpurea extracts on human dendritic 
cells: a cell- and gene-based study. Genomics. 88: 801-808. 
Wang H, Ooi EV, Ang PO Jr (2008) Anti-viral activities of extracts from Hong Kong seaweeds. 
Journal of Zhejiang University SCIENCE B. 9 (12): 969-976. 
Wang WJ, Li DJ, Li J, Zhou WJ (2010). An in vitro study on neuroprotective effects of serum 
containing Gengnianchun decoction and its main monomers against amyloid beta 
protein-induced cellular toxicity. J. Chin. Integr. Med., 8: 67. 
Weiner MA (1984) Secrets of Fijian Medicine; University of California: Berkely, CA, pp 65-67. 
Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A 
infections in the hospitalized elderly. J. Infect. Dis. 172:389–394. 
Williams JE (2001) Review of anti-viral and immunomodulating properties of plants of the 
Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de 
Grado. Altern Med. Rev. 6: 567-579. 
Witvrouw M, de Clercq E (1997) Sulfated polysaccharides extracted from sea algae as potential 
anti-viral drugs. Gen. Pharmacol. 29 (4): 497-511.  
Woelkart K, Bauer R (2007) The role of alkamides as an active principle of Echinacea. Planta 
Med. 73: 615-623. 
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL et al. 2000. 
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus 
vaccine candidate in infancy. J. Infect. Dis. 182 (5): 1331-42. 
Youn UJ, Jang J, Nam J, Lee YJ, Son YM, Shin HJ, Han A, Chang J, Seo E (2011) Anti-
respiratory syncytial virus (RSV) activity of timosaponin A-III from the rhizomes 
of Anemarrhena asphodeloides. Journal of Medicinal Plants Research.. 5 (7): 1062-
1065. 
Zhu W, Ooi VEC, Chan PKS, Ang PO Jr (2003) Isolation and characterization of a sulfated 
polysaccharide from the brown alga Sargassum patens and determination of its anti-
herpes activity. Biochem. Cell Biol. 81 (1): 25-33.  
www.intechopen.com
Human Respiratory Syncytial Virus Infection
Edited by Dr. Bernhard Resch
ISBN 978-953-307-718-5
Hard cover, 246 pages
Publisher InTech
Published online 25, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In this online Open Access book on "Human RSV Infections", several distinguished authors contribute their
experience in respiratory syncytial virology. A major focus lies on the fascinating pathophysiology of RSV and
represents recent and actual work on different mechanisms involved in the complex pathogenesis of the virus.
The second section elucidates epidemiologic and diagnostic aspects of RSV infection covering a more clinical
view of RSV disease. At last, treatment modalities including the search for a vaccine that is still not in sight are
discussed and conclude this book, thus building up a circle that runs from experimental models of RSV related
lung disease over clinical aspects of disease to the latest news of therapeutic and prophylactic approaches to
human RSV infection.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Damian Chukwu Odimegwu, Thomas Grunwald and Charles Okechukwu Esimone (2011). Anti-Respiratory
Syncytial Virus Agents from Phytomedicine, Human Respiratory Syncytial Virus Infection, Dr. Bernhard Resch
(Ed.), ISBN: 978-953-307-718-5, InTech, Available from: http://www.intechopen.com/books/human-respiratory-
syncytial-virus-infection/anti-respiratory-syncytial-virus-agents-from-phytomedicine
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
